357
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Synthesis of novel fused acenaphtopyrimidine hybrid, its photophysical properties and HSA interaction

ORCID Icon
Pages 222-230 | Received 28 May 2021, Accepted 22 Aug 2021, Published online: 13 Sep 2021
 

ABSTRACT

A facile and versatile procedure for the synthesis of novel functionalised 10-(1H-indol-3-yl)acenaphtho[1,2-d]pyrimidin-8-amine (compound 4) has been described. The novel intermediate enone (3) and pyrimidine derivatives (4) were characterised by using FT-IR, NMR and MS. Moreover, the photophysical properties of compound 4 and its interaction with HSA (Human Serum Albumin) have been investigated by means of photometric and fluorimetric titration. Compound 4 showed the increase in fluorescence and hypsochromic shift of its maximum upon the addition of HSA that interaction is supported by molecular docking. Overall, Compound 4 has promising affinity towards HSA which was not previously reported for any fused acenaphtenone–pyrimidine hybrid analogues.

Graphical abstract

Acknowledgments

I specially thank Prof. Dr. Zeynel SEFEROĞLU, Assoc. Prof. M. Gökhan ÇAĞLAYAN and F. Metehan BENLI for the help and support in the interaction studies.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Supplementary Material

Supplemental data for this article can be accessed here.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.